High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents ; volume:22 ; number:1 ; day:2 ; month:1 ; year:2025 ; pages:1-13 ; date:12.2025
Immunity & ageing ; 22, Heft 1 (2.1.2025), 1-13, 12.2025
- Creator
-
Hofstee, Marloes I.
Kaczorowska, Joanna
Postema, Abigail
Zomer, Erna
Waalwijk, Maren van
Jonathans, Gustaaf
Rond, Lia GH de
Smits, Gaby
Hoogen, Lotus L van den
Hartog, Gerco den
Buisman, Anne-Marie
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12979-024-00495-4
- URN
-
urn:nbn:de:101:1-2503082107533.652887665940
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hofstee, Marloes I.
- Kaczorowska, Joanna
- Postema, Abigail
- Zomer, Erna
- Waalwijk, Maren van
- Jonathans, Gustaaf
- Rond, Lia GH de
- Smits, Gaby
- Hoogen, Lotus L van den
- Hartog, Gerco den
- Buisman, Anne-Marie
- SpringerLink (Online service)
Other Objects (12)
Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
Low humoral immune response to the BNT162b2 vaccine against COVID-19 in nursing home residents undergoing hemodialysis: a case–control observational study
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
COVID-19 mRNA booster vaccination induces robust antibody responses but few adverse events among SARS-CoV-2 naïve nursing home residents
Advanced cognitive impairment among older nursing home residents
Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
Low humoral immune response to the BNT162b2 vaccine against COVID-19 in nursing home residents undergoing hemodialysis: a case–control observational study
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
COVID-19 mRNA booster vaccination induces robust antibody responses but few adverse events among SARS-CoV-2 naïve nursing home residents
Advanced cognitive impairment among older nursing home residents
Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
Low humoral immune response to the BNT162b2 vaccine against COVID-19 in nursing home residents undergoing hemodialysis: a case–control observational study
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
COVID-19 mRNA booster vaccination induces robust antibody responses but few adverse events among SARS-CoV-2 naïve nursing home residents